Radius Health, Inc., a biopharmaceutical company, develops and commercializes endocrine and other therapeutics. More Details
Reasonable growth potential and slightly overvalued.
Share Price & News
How has Radius Health's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: RDUS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: RDUS's weekly volatility (8%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: RDUS exceeded the US Biotechs industry which returned 31.4% over the past year.
Return vs Market: RDUS underperformed the US Market which returned 44.2% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Radius Health's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 days ago | Simply Wall StWhen Can We Expect A Profit From Radius Health, Inc. (NASDAQ:RDUS)?
1 month ago | Simply Wall StA Look At Radius Health's (NASDAQ:RDUS) Share Price Returns
7 months ago | Simply Wall StAnalysts Are Updating Their Radius Health, Inc. (NASDAQ:RDUS) Estimates After Its Third-Quarter Results
Is Radius Health undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: RDUS ($18.81) is trading below our estimate of fair value ($78.38)
Significantly Below Fair Value: RDUS is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: RDUS is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: RDUS is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate RDUS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: RDUS has negative assets, so we can't compare its PB Ratio to the US Biotechs industry average.
How is Radius Health forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RDUS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: RDUS is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: RDUS's is expected to become profitable in the next 3 years.
Revenue vs Market: RDUS's revenue (16.9% per year) is forecast to grow faster than the US market (9.2% per year).
High Growth Revenue: RDUS's revenue (16.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if RDUS's Return on Equity is forecast to be high in 3 years time
How has Radius Health performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: RDUS is currently unprofitable.
Growing Profit Margin: RDUS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: RDUS is unprofitable, but has reduced losses over the past 5 years at a rate of 8.9% per year.
Accelerating Growth: Unable to compare RDUS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RDUS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.7%).
Return on Equity
High ROE: RDUS's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
How is Radius Health's financial position?
Financial Position Analysis
Short Term Liabilities: RDUS has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: RDUS has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: RDUS has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: RDUS's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RDUS has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if RDUS has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Radius Health current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate RDUS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate RDUS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if RDUS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RDUS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of RDUS's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
G. Martin (61 yo)
Mr. G. Kelly Martin has been Executive Chairman of Wren Therapeutics Ltd. since 2018. Mr. Martin serves as the Chief Executive Officer, President and Director at Radius Health, Inc. since April 28, 2020. H...
CEO Compensation Analysis
Compensation vs Market: G.'s total compensation ($USD12.15M) is above average for companies of similar size in the US market ($USD2.39M).
Compensation vs Earnings: Insufficient data to compare G.'s compensation with company performance.
Experienced Management: RDUS's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.
Experienced Board: RDUS's board of directors are considered experienced (4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Radius Health, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Radius Health, Inc.
- Ticker: RDUS
- Exchange: NasdaqGM
- Founded: 2003
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$888.634m
- Shares outstanding: 47.24m
- Website: https://www.radiuspharm.com
Number of Employees
- Radius Health, Inc.
- 22 Boston Wharf Road
- 7th Floor
- United States
Radius Health, Inc., a biopharmaceutical company, develops and commercializes endocrine and other therapeutics. The company’s commercial product is TYMLOS, an abaloparatide injection for the treatment of p...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/06/12 10:01|
|End of Day Share Price||2021/06/11 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.